One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)

11:58 19/06/2026

Hong Kong stock "the first stock of innovative drugs for kidney disease" LifeBond Medicine (09637) has introduced 11 top cornerstone investors, creating the strongest lineup in the Hong Kong stock 18A market in recent years.

Hong Kong stock "the first stock of innovative drugs for kidney disease" LIBANG Medicine (09637) was listed from June 18 to June 24, 2026, and is expected to officially start trading on the Hong Kong Stock Exchange at 9 am on June 29. This innovative drug company specializing in kidney disease not only has a complete pipeline matrix of "1 commercial product + 7 clinical stage candidate drugs", but also has gathered 11 cornerstone investors including global sovereign funds, century-old asset management, professional life science funds, and industrial capital under the overall low performance of the Hong Kong stock biopharmaceutical sector, setting a ceiling for the cornerstone lineup in the 18A market in recent years.

New stock preview | How deep is the barrier of Guirewat's radical transformation into the "champion of household energy storage"?

After Musk liked it, he hugged his face and paid out of pocket: GLM-5.2 6 hours globally free, open source will surely win!

IPO landed quickly and is planning to refinance! SpaceX intends to issue at least $20 billion in bonds, and its stock price has experienced a roller coaster.

New stock preview | How deep is the barrier of Guirewat's radical transformation into the "champion of household energy storage"?

After Musk liked it, he hugged his face and paid out of pocket: GLM-5.2 6 hours globally free, open source will surely win!

IPO landed quickly and is planning to refinance! SpaceX intends to issue at least $20 billion in bonds, and its stock price has experienced a roller coaster.